
MPLT Stock Forecast & Price Target
MPLT Analyst Ratings
Bulls say
MapLight Therapeutics is a promising investment due to their strong management team, research partnerships, and potential best-in-class drug for neuropsychiatric disorders with extended patent protection. While their current valuation is low, investors should consider the potential risks and a need for further research on product effectiveness and possible side effects.
Bears say
MapLight Therapeutics is a clinical-stage biopharmaceutical company with a negative outlook due to the early-stage and speculative nature of its drug products, potential for failure in clinical trials, and competition in the neuropsychiatric market. While the company's therapeutic approach targeting neural circuits shows promise, its lack of a proven track record and significant financial resources could be concerning to investors. Additionally, without any approved drugs on the market and a limited pipeline, the company's revenue potential remains uncertain.
This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MPLT Analyst Forecast & Price Prediction
Start investing in MPLT
Order type
Buy in
Order amount
Est. shares
0 shares